Polymerases & Mixes

Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy

Allogeneic chimeric antigen receptor (CAR) T holds the promise of taking this therapeutic approach to broader patient populations while avoiding the intensive manufacturing demands of autologous cell products.
One limitation to delivering an allogeneic CAR T is T-cell receptor (TCR) driven toxicity. In this work, the Bio Med Frontiers expression of a peptide to interfere with TCR signaling was assessed for the generation of allogeneic CAR T cells.
The expression of a truncated CD3ζ peptide was shown to incorporate into the TCR complex and to result in blunted TCR responses. When coexpressed with a natural killer group 2D (NKG2D) CAR, the allogeneic T cells (called CYAD-101) failed to induce graft-versus-host disease in mouse models while maintaining antitumor activity driven by the CAR in vitro and in vivo.
Two clinical grade discrete batches of CYAD-101 cells were produced of single donor apheresis resulting in 48 billion CAR T cells sufficient for the entire dose-escalation phase of the proposed clinical trial.
The 2 batches showed high consistency producing a predominantly CD4+ T-cell population that displayed an effector/central memory phenotype with no evidence of exhaustion markers expression.
These clinical grade CYAD-101 cells secreted cytokines and chemokines in response to ligands expressing target cells in vitro, demonstrating effector function through the CAR. Moreover, CYAD-101 cells failed to respond to TCR stimulation, indicating a lack of allogeneic potential.
This bank of clinical-grade, non-gene-edited, allogeneic CYAD-101 cells are used in the also shrink clinical trial (NCT03692429).

A Retrospective Analysis: Autologous Peripheral Blood Hematopoietic Stem Cell Transplant Combined With Adoptive TCell Therapy for the Treatment of High-Grade B-Cell Lymphoma in Ten Dogs.

  1. In humans, a type of cellular immunotherapy, called adoptive T cell transfer (ACT), can elicit curative responses against hematological malignancies and melanoma. ACT using ex vivo expanded peripheral blood T-cells after multiagent chemotherapy enhances tumor-free survival of dogs with B-cell lymphoma (LSA). Since 2008, our group has been performing autologous peripheral blood hematopoietic stem cell transplants (autoPBHSCT) for the treatment of canine high-grade B-cell LSA, although relapse of residual disease is a common cause of reduced survival in ~70% of treated dogs.
  2. We reasoned that a more aggressive treatment protocol combining CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, autoPBHSCT, and Learn More ACT to treat 10 dogs with B-cell LSA could lead to better outcomes when compared to dogs treated with CHOP chemotherapy and autoPBHSCT alone.
  3. Using this protocol, once dogs achieved complete hematologic reconstitution post-autoPBHSCT, CD3+ CD8+ and CD3+CD4+ T-cells were expanded from the peripheral blood at a commercial laboratory.
  4. Two to four ACT infusions were given to each dog, with a total of 23 infusions given. Infusions were administered with no complications or adverse events.
  5. The median cell dose for all infusions was 5.62 x 106 cells/kg (range: 2.59 x 106-8.55 x 106 cells/kg). 4/10 (40%) of dogs were cured of their disease (defined as disease-free for ≥2 years post-autoPBHSCT). Our results confirm that the autoPBHSCT protocol did not hinder the in vitro expansion of autologous peripheral blood T-cells and that the final product could be administered safely, with no adverse events recorded.
  6. Finally, since only ten dogs were treated, our results can only suggest that the administration of ACT to dogs after multiagent chemotherapy and autoPHSCT did not lead to a statistically significant increase in median disease-free interval and overall survival when compared to dogs who received CHOP chemotherapy and autoPHSCT alone.

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces Tcell response in low-grade gliomas.

 Long-term prognosis of WHO grade II low-grade glioma (LGG) is poor secondary to risk of recurrence and malignant transformation into high-grade glioma. Given the relatively intact immune system of patients with LGG and the slow tumor growth rate, vaccines are an attractive treatment strategy.
 We conducted a pilot study to evaluate the safety and immunological effects of vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line, with poly-ICLC in patients with LGG.
Patients were randomized to receive the vaccines before surgery (Arm 1) or not (Arm 2) and all patients received adjuvant vaccine. Co-primary outcomes were to evaluate the safety and immune response in the tumor.
A total of 17 eligible patients were enrolled – nine into Arm 1 and eight into Arm 2. This regimen was well-tolerated with no regimen-limiting toxicity. Neoadjuvant vaccination induced upregulation of type-1 cytokines and chemokines, and increased activated CD8+ T-cells in peripheral blood. Single-cell RNA/TCR-sequencing detected CD8+ T-cell clones that expanded with effector phenotype and migrated into tumor microenvironment (TME) in response to neoadjuvant vaccination. Mass cytometric analyses detected increased tissue resident-like CD8+ T-cells with effector memory phenotype in TME following the neoadjuvant vaccination.
The current regimen induces effector CD8+ T-cell response in peripheral blood and enables vaccine-reactive CD8+ T-cells to migrate into TME. Further refinements of the regimen may have to be integrated into future strategies.
Trial registration:ClinicalTrials.gov NCT02549833.
Funding:NIH (1R35NS105068, 1R21CA233856), Dabbiere Foundation, Parker Institute for Cancer Immunotherapy, and Daiichi Sankyo Foundation of Life Science.
Keywords: Brain cancer; Cancer immunotherapy; Oncology; T cells; Vaccines.

TCell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.

  • Despite decades of research, pediatric central nervous system (CNS) tumors remain the most debilitating, difficult to treat, and deadliest cancers. Current therapies, including radiation, chemotherapy, and/or surgery, are unable to cure these diseases and are associated with serious adverse effects and long-term impairments. Immunotherapy using chimeric antigen receptor (CAR) T cells has the potential to elucidate therapeutic antitumor immune responses that improve survival without the devastating adverse effects associated with other therapies.
  • Yet, despite the outstanding performance of CAR T cells against hematologic malignancies, they have shown little success targeting brain tumors. This lack of efficacy is due to a scarcity of targetable antigens, interactions with the immune microenvironment, and physical and biological barriers limiting the homing and trafficking of CAR T cells to brain tumors.
  • In this review, we summarize experiences with CAR T-cell therapy for pediatric CNS tumors in preclinical and clinical settings and focus on the current roadblocks and novel strategies to potentially overcome those therapeutic challenges.

A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomas.

Chemotherapeutic drugs such as the alkylating agent Temozolomide (TMZ), in addition to reducing tumor mass, can also sensitize tumors to immune recognition by transient upregulation of multiple stress induced NKG2D ligands (NKG2DL).
However, the potential for an effective response by innate lymphocyte effectors such as NK and γδ T cells that recognize NKG2DL is limited by the drug’s concomitant lymphodepleting effects.
We have previously shown that modification of γδ T cells with a methylguanine DNA methyltransferase (MGMT) transgene confers TMZ resistance via production of O6-alkylguanine DNA alkyltransferase (AGT) thereby enabling γδ T cell function in therapeutic concentrations of TMZ.

T-Pro Gradient Gel Solution kit 4-12%

JB02-B110M T-Pro Biotechnology 250ml+100ml/kit 60 EUR

T-Pro Cell Counting Kit (CCK8)

JK95-C008L T-Pro Biotechnology 5ml*20/BT 1000 EUR

T-Pro Cell Counting Kit (CCK8)

JK95-C008M T-Pro Biotechnology 5ml*2/BT 120 EUR

T-Pro Cell Counting Kit (CCK8)

JK95-C008S T-Pro Biotechnology 1ml*5/BT 80 EUR

T-Pro Total Exosome Isolation reagent (from cell culture media)

JO66-V001M T-Pro Biotechnology 500ml/BT 800 EUR

T-Pro Total Exosome Isolation reagent (from cell culture media)

JO66-V001S T-Pro Biotechnology 100ml/BT 200 EUR

T-Pro Stacking Buffer

JB03-C002 T-Pro Biotechnology 500ml/BT 182.4 EUR

T-Pro MycoClean spray

JT90-R002 T-Pro Biotechnology 500ml/BT 172.8 EUR

T-Pro Blocking Buffer

JK92-W005 T-Pro Biotechnology 500ml/BT 60 EUR

ActiveMax® Streptavidin μBeads, premium grade (for cells)


T-Pro EZ Gel Solution 8%

JB02-B008M T-Pro Biotechnology 500ml/BT 266.4 EUR

T-Pro EZ Gel Solution 8%

JB02-B008S T-Pro Biotechnology 100ml/BT 162 EUR

T-Pro EZ Gel Solution 10%

JB02-B010M T-Pro Biotechnology 500ml/BT 266.4 EUR

T-Pro EZ Gel Solution 10%

JB02-B010S T-Pro Biotechnology 100ml/BT 162 EUR

T-Pro EZ Gel Solution 12%

JB02-B012M T-Pro Biotechnology 500ml/BT 266.4 EUR

T-Pro EZ Gel Solution 12%

JB02-B012S T-Pro Biotechnology 100ml/BT 162 EUR

T-Pro EZ Gel Solution 15%

JB02-B015M T-Pro Biotechnology 500ml/BT 266.4 EUR

T-Pro EZ Gel Solution 15%

JB02-B015S T-Pro Biotechnology 100ml/BT 162 EUR
In this study, we tested this strategy which we have termed Drug Resistant Immunotherapy (DRI) to examine whether combination therapy of TMZ and MGMT-modified γδ T cells could improve survival outcomes in four human/mouse xenograft models of primary and refractory GBM.
Our results confirm that DRI leverages the innate response of γδ T cells to chemotherapy-induced stress associated antigen expression and achieves synergies that are significantly greater than either individual approach.

Leave a Reply

Your email address will not be published. Required fields are marked *